New Medical Device Company Excimer Therapies Debuts at 2018 American Academy of Dermatology Annual Meeting and Inks Exclusive Agreement for U.S. Distribution Rights to the exciplex® Treatment System
SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Excimer Therapies Inc., a medical device company focused on the treatment of certain conditions that are amenable to phototherapy treatment, has been awarded exclusive U.S. distribution rights for the Clarteis SAS exciplex®, the lightest and most powerful phototherapy treatment device for psoriasis, atopic dermatitis (eczema), vitiligo and leukoderma. Excimer Therapies officially enters the market and will demonstrate the exciplex at its booth (#5429) at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, from Feb. 16-18. The event marks the first time the exciplex is available for sale in the U.S.
Excimer Therapies' CEO and President Fred Hill says, "We are unveiling Excimer Therapies today to address the market need for medical devices that treat dermatological and other unmet medical conditions. We are delighted to be working with Clarteis as the exclusive U.S. importer of its exceptional medical device, the exciplex. We are hoping to help dermatologists offer an adjunct or alternative to the current therapies that treat the large patient populations suffering from psoriasis, atopic dermatitis, vitiligo and leukoderma."
It is estimated that over 7 million people have psoriasis in the U.S. according to the National Psoriasis Foundation; about 18 million have atopic dermatitis according to the National Eczema Association; and 5 million have vitiligo and/or leukoderma according to the National Vitiligo Foundation. The excimer light system produces ultraviolet wavelengths at 308 nanometers — or narrowband UVB — and has been shown in clinical trials to reduce and/or clear the plaques and redness of psoriasis and atopic dermatitis, as well as return skin color to vitiligo and leukoderma patients. It may be used alone to treat psoriasis or eczema or in conjunction with current therapies to treat the more difficult and stubborn areas of those skin conditions that may be resistant to clearance under biological therapy alone. Vitiligo, which affects all races but is most visible in individuals with darker skin, has no FDA-approved pharmaceuticals specifically for treatment, however, excimer light therapy has been scientifically shown to return skin pigmentation with treatments over time.
Excimer Therapies' Chief Financial Officer Gilles Godard says, "We are very pleased to represent and sell the exciplex device from Clarteis. The company has done a remarkable job in engineering this to be lightweight, powerful, and still user-friendly. We believe the exciplex price and maintenance schedule will produce a much better return on investment for our users when compared to laser-based devices."
The exciplex is touch-screen controlled, ergonomically designed, and weighs only two pounds, making it easy to use and hold. It has a large, 25-square-centimeter treatment window, producing a maximum output of 2,500 milliwatts, which can be adjusted to the patients' needs with the touch-screen controlled software, disposable masks and reducers. It also has a built-in programmable maximum erythema dose (MED) determination mode to help doctors determine quickly and easily the right MED dose of UVB for the patient.
Clarteis SAS is a French company and an innovator in the field of excimer light systems. The company recently received FDA clearance to market the device in the U.S. Clarteis also has both the CE Mark and ISO 13485 certification in Europe. The exciplex from Clarteis is a narrowband, 308-nanometer UVB excimer light system with patent-pending technology, and the device is already distributed in 11 other countries, including Japan, India and Australia.
About Excimer Therapies
Excimer Therapies is a privately-held, medical device company with headquarters in San Diego, California, focused on the management of certain conditions that are amenable to phototherapy treatment. It is the exclusive U.S. distributor of Clarteis' exciplex phototherapy device system, which produces 308-nanometer UVB light to treat specific skin conditions — such as psoriasis, atopic dermatitis (eczema), vitiligo and leukoderma — with "the healing power of light®." For more information about Excimer Therapies, please visit our website at www.ExcimerTherapies.com
Contact:
Fred Hill
CEO and President
Excimer Therapies Inc.
858-255-0175
[email protected]
www.ExcimerTherapies.com
SOURCE Excimer Therapies
Share this article